APN-401 is under clinical development by InvIOs and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APN-401’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APN-401 is under development for the treatment of various solid tumors. It is an autologous cell therapy. The drug candidate is administered through intravenous route and acts by targeting the E3 ubiquitin ligase Cbl-b.
It was under development for the treatment of melanoma, renal carcinoma (kidney), metastatic pancreatic cancer, metastatic colorectal cancer.
InvIOs a subsidiary of APEIRON Biologics AG, is a biotech company that focused on the discovery and development of cancer immunotherapies. InvIOs is headquartered in Vienna, Austria.
For a complete picture of APN-401’s drug-specific PTSR and LoA scores, buy the report here.